Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)

Inclusion Criteria: * Age ≥ 18 years * Able to give written consent * Covered by French Social Security * HIV-infected (infection attested by the patient's chart) * Patients treated by HAART for at least 6 months, with a viral load inferior to 50 copies/mL on at least 2 last visits * Patients without any treatment for HIV for at least 6 months and without any indication to start a treatment in the following 3 months * Patients followed for their HIV-infection in an ANRS center and whose home is close to the center in case of influenza-like illness, consultation and hospitalization in the center where he is followed if necessary * For women with childbearing potential, using an effective method of contraception, and willing to undergo urine pregnancy tests prior to each vaccination. Exclusion Criteria: * Pregnancy * Receipt of chemotherapy, immunotherapy (IL2, IL7, IV Ig), or corticosteroids within 3 months prior to enrolment * Thrombopenia inferior to 20 000/mm3 * Febrile episode (at least 38°C rectal or if at least 37,5°C measured orally) within one week prior to vaccination * Opportunistic infection (treated for less than 1 month) * Co-infection with HCV and treated with IFNa * Influenza (clinically or virologically documented) in the last 6 months * History of documented auto-immune disease (lupus, systemic inflammatory disease, ...) * Child C cirrhosis * Solid organ transplant recipient * Intolerance to 1 component of the vaccine * Other immunization received within 3 weeks prior to inclusion or planned until after the last vaccine injection.